Trial Profile
A Multicenter, Randomized, Double-blind, Sham-controlled, Comparative Study of SI-6603 in Subjects With Lumbar Disc Herniation (Phase 3)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Apr 2024
Price :
$35
*
At a glance
- Drugs Condoliase (Primary)
- Indications Intervertebral disc displacement
- Focus Registrational; Therapeutic Use
- Acronyms Discovery 6603
- Sponsors Seikagaku Corporation
- 08 Apr 2024 According to a Ferring Pharmaceuticals Media Release, data from this study was presented at the American Society of Interventional Pain Physicians (ASIPP) Annual Meeting.
- 08 Apr 2024 Results presented in a Ferring Pharmaceuticals Media Release.
- 26 May 2023 Results presented in a Ferring Pharmaceuticals media release.